Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083595498> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3083595498 abstract "Prostate cancer (PC) is the most frequently diagnosed cancer among men in the United States and is the 3rd cause of cancer mortality. Despite advances in the treatment and understanding of pathogenesis, patients with metastatic PC invariably progress to a lethal stage of castration-resistant prostate cancer (CRPC). Inhibition of androgen signaling remains crucial for the treatment of CRPC, but novel treatment strategies are urgently needed. ONC201 is a first-in-class, selective inhibitor of dopamine receptor D2 that upregulates death-receptor 5 and induces apoptosis. ONC201 induced apoptosis in PC cell lines and showed synergy with enzalutamide, docetaxel and everolimus (Lev A Mol Cancer Res 2018). Darolutamide (DARO) is a novel androgen receptor (AR) antagonist approved for treatment of patients with non-metastatic CRPC. DARO has higher affinity to AR and preclinical activity against enzalutamide-resistant PC cell lines including AR variants associated with enzalutamide agonism (Borgmann H Eur Urol 2018). We treated human PC cell lines (LNCAP [castration sensitive, AR wild-type], 22Rv1 [castration-resistant cell line that expresses AR splice variant AR-V7], DU145 [AR negative], PC3 [AR negative]) with DARO alone and combined with ONC201. Single-agent DARO decreased PC cell viability in Cell-Titer-Glo assays (IC50s of 10 and 693 nM for LNCAP and DU145, respectively). ONC201 showed strong synergism with DARO in LNCAP cells (combination indices Citation Format: Fabio Tavora, Lanlan Zhou, Ali Amin, Safran Howard, Navaraj Arunasalam, Andre de Souza, Anthony Mega, Dragan Golijanin, Wafik El-Deiry, Benedito Carneiro. ONC201 shows synergistic effect with the androgen receptor AR-inhibitor darotulamide in prostate cancer models [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1836." @default.
- W3083595498 created "2020-09-11" @default.
- W3083595498 creator A5008196559 @default.
- W3083595498 creator A5036882735 @default.
- W3083595498 creator A5059604250 @default.
- W3083595498 creator A5061279381 @default.
- W3083595498 creator A5062656170 @default.
- W3083595498 creator A5069923958 @default.
- W3083595498 creator A5071764656 @default.
- W3083595498 creator A5075201353 @default.
- W3083595498 creator A5078851944 @default.
- W3083595498 creator A5091701598 @default.
- W3083595498 date "2020-08-13" @default.
- W3083595498 modified "2023-09-25" @default.
- W3083595498 title "Abstract 1836: ONC201 shows synergistic effect with the androgen receptor AR-inhibitor darotulamide in prostate cancer models" @default.
- W3083595498 doi "https://doi.org/10.1158/1538-7445.am2020-1836" @default.
- W3083595498 hasPublicationYear "2020" @default.
- W3083595498 type Work @default.
- W3083595498 sameAs 3083595498 @default.
- W3083595498 citedByCount "0" @default.
- W3083595498 crossrefType "proceedings-article" @default.
- W3083595498 hasAuthorship W3083595498A5008196559 @default.
- W3083595498 hasAuthorship W3083595498A5036882735 @default.
- W3083595498 hasAuthorship W3083595498A5059604250 @default.
- W3083595498 hasAuthorship W3083595498A5061279381 @default.
- W3083595498 hasAuthorship W3083595498A5062656170 @default.
- W3083595498 hasAuthorship W3083595498A5069923958 @default.
- W3083595498 hasAuthorship W3083595498A5071764656 @default.
- W3083595498 hasAuthorship W3083595498A5075201353 @default.
- W3083595498 hasAuthorship W3083595498A5078851944 @default.
- W3083595498 hasAuthorship W3083595498A5091701598 @default.
- W3083595498 hasConcept C121608353 @default.
- W3083595498 hasConcept C126322002 @default.
- W3083595498 hasConcept C2776438761 @default.
- W3083595498 hasConcept C2776551883 @default.
- W3083595498 hasConcept C2779723316 @default.
- W3083595498 hasConcept C2780192828 @default.
- W3083595498 hasConcept C2781190966 @default.
- W3083595498 hasConcept C502942594 @default.
- W3083595498 hasConcept C61367390 @default.
- W3083595498 hasConcept C71924100 @default.
- W3083595498 hasConcept C98274493 @default.
- W3083595498 hasConceptScore W3083595498C121608353 @default.
- W3083595498 hasConceptScore W3083595498C126322002 @default.
- W3083595498 hasConceptScore W3083595498C2776438761 @default.
- W3083595498 hasConceptScore W3083595498C2776551883 @default.
- W3083595498 hasConceptScore W3083595498C2779723316 @default.
- W3083595498 hasConceptScore W3083595498C2780192828 @default.
- W3083595498 hasConceptScore W3083595498C2781190966 @default.
- W3083595498 hasConceptScore W3083595498C502942594 @default.
- W3083595498 hasConceptScore W3083595498C61367390 @default.
- W3083595498 hasConceptScore W3083595498C71924100 @default.
- W3083595498 hasConceptScore W3083595498C98274493 @default.
- W3083595498 hasLocation W30835954981 @default.
- W3083595498 hasOpenAccess W3083595498 @default.
- W3083595498 hasPrimaryLocation W30835954981 @default.
- W3083595498 hasRelatedWork W10235104 @default.
- W3083595498 hasRelatedWork W10785221 @default.
- W3083595498 hasRelatedWork W11467293 @default.
- W3083595498 hasRelatedWork W18971000 @default.
- W3083595498 hasRelatedWork W20811490 @default.
- W3083595498 hasRelatedWork W2606708 @default.
- W3083595498 hasRelatedWork W3847876 @default.
- W3083595498 hasRelatedWork W5984520 @default.
- W3083595498 hasRelatedWork W8802154 @default.
- W3083595498 hasRelatedWork W16813516 @default.
- W3083595498 isParatext "false" @default.
- W3083595498 isRetracted "false" @default.
- W3083595498 magId "3083595498" @default.
- W3083595498 workType "article" @default.